vs

Side-by-side financial comparison of BLACKBERRY Ltd (BB) and CareDx, Inc. (CDNA). Click either name above to swap in a different company.

BLACKBERRY Ltd is the larger business by last-quarter revenue ($141.8M vs $117.7M, roughly 1.2× CareDx, Inc.). BLACKBERRY Ltd runs the higher net margin — 9.7% vs 2.4%, a 7.3% gap on every dollar of revenue. On growth, CareDx, Inc. posted the faster year-over-year revenue change (39.0% vs -0.8%). BLACKBERRY Ltd produced more free cash flow last quarter ($17.4M vs $514.0K). Over the past eight quarters, BLACKBERRY Ltd's revenue compounded faster (17.8% CAGR vs 12.9%).

BlackBerry Limited, formerly Research In Motion (RIM), is a Canadian software company specializing in secure communications and the Internet of Things (IoT). Founded in 1984, it developed the BlackBerry brand of two-way pagers, smartphones, and tablets. The company later transitioned to providing software and services and holds critical software application patents.

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

BB vs CDNA — Head-to-Head

Bigger by revenue
BB
BB
1.2× larger
BB
$141.8M
$117.7M
CDNA
Growing faster (revenue YoY)
CDNA
CDNA
+39.8% gap
CDNA
39.0%
-0.8%
BB
Higher net margin
BB
BB
7.3% more per $
BB
9.7%
2.4%
CDNA
More free cash flow
BB
BB
$16.9M more FCF
BB
$17.4M
$514.0K
CDNA
Faster 2-yr revenue CAGR
BB
BB
Annualised
BB
17.8%
12.9%
CDNA

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
BB
BB
CDNA
CDNA
Revenue
$141.8M
$117.7M
Net Profit
$13.7M
$2.8M
Gross Margin
77.5%
Operating Margin
8.4%
1.0%
Net Margin
9.7%
2.4%
Revenue YoY
-0.8%
39.0%
Net Profit YoY
224.5%
EPS (diluted)
$0.02
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BB
BB
CDNA
CDNA
Q1 26
$117.7M
Q4 25
$141.8M
$108.4M
Q3 25
$129.6M
$100.1M
Q2 25
$121.7M
$86.7M
Q1 25
$141.7M
$84.7M
Q4 24
$143.6M
$86.6M
Q3 24
$126.2M
$82.9M
Q2 24
$123.4M
$92.3M
Net Profit
BB
BB
CDNA
CDNA
Q1 26
$2.8M
Q4 25
$13.7M
$-4.1M
Q3 25
$13.3M
$1.7M
Q2 25
$1.9M
$-8.6M
Q1 25
$-7.4M
$-10.4M
Q4 24
$-10.5M
$87.7M
Q3 24
$-19.7M
$-10.6M
Q2 24
$-41.4M
$-4.6M
Gross Margin
BB
BB
CDNA
CDNA
Q1 26
Q4 25
77.5%
Q3 25
74.5%
Q2 25
74.2%
Q1 25
73.5%
Q4 24
78.1%
Q3 24
70.2%
Q2 24
72.9%
Operating Margin
BB
BB
CDNA
CDNA
Q1 26
1.0%
Q4 25
8.4%
-5.6%
Q3 25
8.9%
-0.2%
Q2 25
1.6%
-12.8%
Q1 25
-5.6%
-15.8%
Q4 24
13.6%
97.5%
Q3 24
1.7%
-16.6%
Q2 24
-10.5%
-7.9%
Net Margin
BB
BB
CDNA
CDNA
Q1 26
2.4%
Q4 25
9.7%
-3.8%
Q3 25
10.3%
1.7%
Q2 25
1.6%
-9.9%
Q1 25
-5.2%
-12.2%
Q4 24
-7.3%
101.3%
Q3 24
-15.6%
-12.8%
Q2 24
-33.5%
-5.0%
EPS (diluted)
BB
BB
CDNA
CDNA
Q1 26
$0.05
Q4 25
$0.02
$-0.08
Q3 25
$0.02
$0.03
Q2 25
$0.00
$-0.16
Q1 25
$-0.01
$-0.19
Q4 24
$-0.02
$1.60
Q3 24
$-0.03
$-0.20
Q2 24
$-0.07
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BB
BB
CDNA
CDNA
Cash + ST InvestmentsLiquidity on hand
$304.2M
$77.9M
Total DebtLower is stronger
$196.2M
Stockholders' EquityBook value
$741.1M
Total Assets
$1.2B
$411.1M
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BB
BB
CDNA
CDNA
Q1 26
$77.9M
Q4 25
$304.2M
$177.2M
Q3 25
$290.5M
$194.2M
Q2 25
$306.6M
$186.3M
Q1 25
$337.8M
$230.9M
Q4 24
$220.0M
$260.7M
Q3 24
$211.0M
$240.9M
Q2 24
$229.0M
$228.9M
Total Debt
BB
BB
CDNA
CDNA
Q1 26
Q4 25
$196.2M
Q3 25
$195.9M
Q2 25
$195.6M
Q1 25
$195.3M
Q4 24
Q3 24
$0
Q2 24
$0
Stockholders' Equity
BB
BB
CDNA
CDNA
Q1 26
Q4 25
$741.1M
$303.1M
Q3 25
$725.1M
$311.1M
Q2 25
$725.1M
$327.4M
Q1 25
$719.9M
$379.3M
Q4 24
$725.2M
$378.4M
Q3 24
$732.1M
$273.2M
Q2 24
$742.6M
$264.7M
Total Assets
BB
BB
CDNA
CDNA
Q1 26
$411.1M
Q4 25
$1.2B
$413.2M
Q3 25
$1.2B
$432.3M
Q2 25
$1.2B
$444.3M
Q1 25
$1.3B
$489.6M
Q4 24
$1.3B
$491.1M
Q3 24
$1.3B
$477.0M
Q2 24
$1.3B
$466.8M
Debt / Equity
BB
BB
CDNA
CDNA
Q1 26
Q4 25
0.26×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.27×
Q4 24
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BB
BB
CDNA
CDNA
Operating Cash FlowLast quarter
$18.3M
$4.3M
Free Cash FlowOCF − Capex
$17.4M
$514.0K
FCF MarginFCF / Revenue
12.3%
0.4%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
1.34×
1.54×
TTM Free Cash FlowTrailing 4 quarters
$42.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BB
BB
CDNA
CDNA
Q1 26
$4.3M
Q4 25
$18.3M
$21.4M
Q3 25
$3.9M
$37.4M
Q2 25
$-18.0M
$9.9M
Q1 25
$41.6M
$-26.6M
Q4 24
$6.0M
$21.9M
Q3 24
$-16.0M
$12.5M
Q2 24
$-15.1M
$18.9M
Free Cash Flow
BB
BB
CDNA
CDNA
Q1 26
$514.0K
Q4 25
$17.4M
Q3 25
$3.1M
Q2 25
$-18.9M
Q1 25
$41.2M
Q4 24
$5.2M
Q3 24
$-16.5M
Q2 24
$-16.5M
FCF Margin
BB
BB
CDNA
CDNA
Q1 26
0.4%
Q4 25
12.3%
Q3 25
2.4%
Q2 25
-15.5%
Q1 25
29.1%
Q4 24
3.6%
Q3 24
-13.1%
Q2 24
-13.4%
Capex Intensity
BB
BB
CDNA
CDNA
Q1 26
Q4 25
0.6%
Q3 25
0.6%
Q2 25
0.7%
Q1 25
0.3%
Q4 24
0.6%
Q3 24
0.4%
Q2 24
1.1%
Cash Conversion
BB
BB
CDNA
CDNA
Q1 26
1.54×
Q4 25
1.34×
Q3 25
0.29×
22.30×
Q2 25
-9.47×
Q1 25
Q4 24
0.25×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BB
BB

QNX$68.7M48%
Secure Communication$67.0M47%
Licensing$6.1M4%

CDNA
CDNA

Financial Results Total$85.0M72%
Patient and digital solutions revenue$16.0M14%
Product revenue$10.3M9%
Other$6.4M5%

Related Comparisons